{"id":"artesunate-comparator","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL361497","moleculeType":"Small molecule","molecularWeight":"384.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Artesunate is a semi-synthetic derivative of artemisinin, a natural compound from Artemisia annua. It works by being activated in the acidic food vacuole of malaria parasites, where it generates highly reactive oxygen species and forms covalent bonds with parasite proteins, leading to rapid parasite death. This mechanism is effective against multiple Plasmodium species and has shown activity against other parasites and some cancer cell lines.","oneSentence":"Artesunate is an artemisinin derivative that generates reactive oxygen species and alkylates parasite proteins, killing malaria parasites and other pathogens.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:18:32.235Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Malaria (all Plasmodium species, including severe malaria)"},{"name":"Uncomplicated malaria (artemisinin-based combination therapy)"}]},"trialDetails":[{"nctId":"NCT04675931","phase":"PHASE2","title":"To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-03-07","conditions":"Severe Malaria","enrollment":254},{"nctId":"NCT06853184","phase":"PHASE2","title":"Study Evaluating the Efficacy and Safety of Artesunate","status":"RECRUITING","sponsor":"Amivas Inc.","startDate":"2025-08-01","conditions":"CMV Infection","enrollment":90},{"nctId":"NCT05764746","phase":"PHASE2, PHASE3","title":"Triple Artemisinin-based Combination Therapy for Delaying Drug Resistance Development - a Randomized Clinical Trial","status":"RECRUITING","sponsor":"Muhimbili University of Health and Allied Sciences","startDate":"2023-05-01","conditions":"Uncomplicated Plasmodium Falciparum Malaria","enrollment":384},{"nctId":"NCT05441410","phase":"PHASE1, PHASE2","title":"Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in Adults","status":"NOT_YET_RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2025-06-01","conditions":"Malaria","enrollment":30},{"nctId":"NCT02671175","phase":"PHASE3","title":"Post-discharge Malaria Chemoprevention(PMC) Study","status":"COMPLETED","sponsor":"Liverpool School of Tropical Medicine","startDate":"2016-05-20","conditions":"Malaria, Severe Anemia","enrollment":1049},{"nctId":"NCT01845701","phase":"PHASE3","title":"Artemisinin-Based Antimalarial Combinations and Clinical Response in Cameroon","status":"COMPLETED","sponsor":"University of Yaounde 1","startDate":"2010-03","conditions":"Malaria","enrollment":720},{"nctId":"NCT00894374","phase":"PHASE1","title":"Bioequivalence Study Comparing Artesunate Tablet To Arsuamoon® Tablets (Guilin-China) In Healthy Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-06","conditions":"Falciparum Malaria","enrollment":40},{"nctId":"NCT00646126","phase":"PHASE3","title":"Antimalarial Treatments for Clearing Low Density P. Falciparum and Its Impact on Malaria Transmission","status":"COMPLETED","sponsor":"Tropical Medicine Research Institute","startDate":"2005-08","conditions":"Plasmodium Falciparum, Asymptomatic Parataemia, Sub Patent Parasitaemia","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":29,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Artesunic acid","Dihydroartemisinin (DHA)","Artemisinin","Imatinib. Infliximab","Artesunate for Injection"],"phase":"marketed","status":"active","brandName":"Artesunate (Comparator)","genericName":"Artesunate (Comparator)","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Artesunate is a small molecule used to treat conditions such as malaria, severe anemia, and falciparum malaria. Its exact mechanism of action is currently unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}